# The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

> **NCT04475107** · PHASE2 · COMPLETED · sponsor: **Shin Poong Pharmaceutical Co. Ltd.** · enrollment: 113 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Pyronaridine-Artesunate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04475107
- **Lead sponsor:** Shin Poong Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-09
- **Primary completion:** 2021-03-25
- **Final completion:** 2021-04-15
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2021-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04475107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04475107, "The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04475107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*